Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMS-03305293 plus temozolomide in adults with recurrent glioblastoma or diffuse glioma
NL-OMON56287Phase 2Recruiting
- Sponsor
- Nerviano Medical Sciences
- Start
- Mar 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of itareparib and temozolomide in diffuse midline glioma (DMG) and glioblastoma (GBM) (2 arms), sponsored by Nerviano Medical Sciences. Primary endpoints: First cycle dose-limiting toxicities and Objective response rate. Started Mar 2022; status: recruiting.
02
Drugs
itareparibtemozolomide
03
Conditions
diffuse midline glioma (DMG)glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON56287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56287.